Literature DB >> 23358320

Microwave-assisted improved synthesis of pyrrolo[2,3,4-kl]acridine and dihydropyrrolo[2,3,4-kl]acridine derivatives catalyzed by silica sulfuric acid.

Chengpao Cao1, Changliang Xu, Wei Lin, Xuemei Li, Minghua Hu, Juxian Wang, Zhibin Huang, Daqing Shi, Yucheng Wang.   

Abstract

An improved synthesis of multifunctionalized pyrrolo[2,3,4-kl]acridine derivatives with different substituted patterns using silica sulfuric acid (SSA) as a heterogeneous catalyst under microwave irradiation conditions was developed. The reaction could be conducted by using readily available and inexpensive substrates within short periods of 12-15 min. under microwave irradiation. Compared with the conventional methods, the remarkable advantages of this method are milder reaction conditions, operational simplicity, higher yields, short reaction times, and an environmentally friendly procedure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358320      PMCID: PMC6269803          DOI: 10.3390/molecules18021613

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Acridine derivatives were primarily used as stains for dye manufacturing (e.g., acridine orange) until their fluorescence and chemiluminescence properties found numerous other applications [1,2,3]. Such acridines have demonstrated important biological activity [4], including activity against cancer [5] due to their ability to intercalate into DNA and disrupt unwanted cellular processes [6]. This unique property of acridines has been exploited in many areas of medicine. As a result, significant biological activity toward viruses [7], bacteria [8], parasites [9,10], fungus [11], Alzheimer’s disease [12], and HIV/AIDS [13] has also been reported. Pyrrolo[2,3,4-kl]acridine derivatives have been isolated from a Plakortis sponge and showed biological activities [14,15]. Although there have been some reports on the synthesis of these molecules [16,17], those methods require multistep syntheses. Recently, we [18] and Tu [19] reported the one-pot synthesis of pyrrolo[2,3,4-kl]acridine derivatives catalyzed by L-proline or AcOH, respectively. However, these methods required the use of toluene or acetic acid as solvents. Thus, there is a need for the development of concise and green methods for the construction of this heterocyclic skeleton. The need to reduce the amount of toxic waste and by-product arising from chemical process requires increasing emphasis on the use of less toxic and environmentally compatible materials in the design of new synthetic methods. One of the most promising approaches in organic synthesis is the use of reusable heterogeneous catalysts because of their environmental, economical, and industrial aspects [20]. The development of efficient methods using recoverable and reusable catalysts is an important goal in organic synthesis. Up to now, several reusable and heterogeneous catalysts have been designed and used. One useful example is silica sulfuric acid (SSA), which has been widely studied in recent years [21,22,23], in a variety of reactions such as cross-Aldol condensation [24], deacylation [25], selective oxidation [26], Michael addition [27] and functional group protection [28]. In our previous works, SSA was used as an efficient catalyst for the acetylation of aldehydes and sugars [29]. As a continuation of our interest in organic reactions catalyzed by solid acids [29,30], herein, we report the microwave-assisted green synthesis of pyrrolo[2,3,4-kl]acridine-1-one derivatives catalyzed by SSA in ethanol.

2. Results and Discussion

In a preliminary study, we optimized the reaction conditions, including reaction solvents, temperature, catalyst and amount of SSA catalyst using isatin (1a), and 3-(4-t-butylphenylamino)-5,5-dimethylcyclohex-2-enone (2a) as model reactants (Scheme 1). The reaction mixture, which was composed of a 1:1 mixture of 1a to 2a, was tested under different conditions. The results are summarized in Table 1.
Scheme 1

The model reaction.

Table 1

Optimization of the reaction conditions for the synthesis of 3a.

EntrySolventCatalyst T (°C)Time (min)Yield a (%)
1ethanol-1101523
2ethanolSSA (0.02 g)1101591
3AcOHSSA (0.02 g)1101585
4H2OSSA (0.02 g)1101581
5ethylene glycolSSA (0.02 g)1101587
6tolueneSSA (0.02 g)1101591
7ethanolHCl (0.5 mL)1101578
8ethanolH2SO4 (0.5 mL)1101559
9ethanolI2 (0.02 g)1101573
10ethanolL-proline (10 mol%)1101540
11ethanolSSA (0.03 g)1101590
12ethanolSSA (0.04 g)1101591
13ethanolSSA (0.01 g)1101576
14ethanolSSA (0.02 g)901571
15ethanolSSA (0.02 g)1001585
16ethanolSSA (0.02 g)1201587
17ethanolSSA (0.02 g)110877
18ethanolSSA (0.02 g)1101087
19ethanolSSA (0.02 g)1101291
20ethanolSSA (0.02 g)1102089

a Yield was determined by HPLC-MS.

The model reaction. Optimization of the reaction conditions for the synthesis of 3a. a Yield was determined by HPLC-MS. The optimization process revealed that the reactions did not proceed in ethanol under catalyst-free conditions (Table 1, entry 1). Pleasingly, the target compound 3a was obtained in ethanol with 0.02 g SSA as catalyst (Table 1, entry 2). To improve the yield, different solvents were evaluated. The results indicated that ethanol provided much better results than AcOH, ethylene glycol or water (Table 1, entries 2–5). The non-polar solvent toluene gave the same yield (Table 1, entry 6). Considering the toxicity of toluene, ethanol was selected as the preferred reaction solvent. Several other catalysts were also evaluated for their catalytic efficiency in the current reaction. Common acids (H2SO4 and HCl) and other catalysts (I2 or L-proline) can catalyze this reaction with low yields (Table 1, entries 7–10). The results revealed that SSA was the optimal catalyst with the product being isolated in 91% yield (Table 1, entry 2). Subsequently, we proceeded to evaluate the amount of SSA required for this reaction. When 0.02 g of silica gel was used, the reaction of 3a proceeded in good yield (91%, Table 1, entry 2). The reaction yield remained unchanged when we increased the amount of SSA (Table 1, entries 11 and 12), but the yield was lower when the amount of SSA was decreased (Table 1, entry 13), therefore, 0.02 g of SSA is sufficient to initiate the reaction. To identify the optimum reaction temperature, the reaction was carried out with 0.02 g SSA at 90 °C, 100 °C, 110 °C and 120 °C, providing the product 3a in yields of 71%, 85%, 91% and 87% (Table 1, entries 14, 15, 2 and 16), respectively, so the most suitable reaction temperature for this reaction is 110 °C. Finally, to optimize the reaction time, the reaction was carried out with 0.02 g SSA at 110 °C and the reaction time used was 8 min, 10 min, 12 min, 15 min and 20 min, respectively. It was found that the reaction can proceed smoothly in 12 min (Table 1, entry 19), while prolonging the reaction time did not enhance the yield of the product (Table 1, entries 2 and 20). Thus, the optimum conditions required the use of 0.02 g SSA as catalyst in ethanol as solvent at 110 °C and a reaction time of 12 min. Having established the optimal conditions we proceeded to investigate the substrate scope of the transformation. As shown in Table 2, substituents such as bromo, chloro, fluoro on the isatin ring, and t-butyl or phenyl groups bearing either electron-withdrawing or electron-donating groups on the enaminone ring, were well tolerated under these reaction conditions, leading to the final products in satisfactory yields (up to 93%).
Table 2

Synthesis of dihydropyrrolo[2,3,4-kl]acridines 3.

EntryProductR1R2Time (min)Isolated Yield (%)
1 3a H4-t-BuC6H41291
2 3b H3,5-(CH3)2C6H31292
3 3c H2-CH3CH2C6H41292
4 3d H3-Cl-4-FC6H31589
5 3e 5-Cl4-CH3OC6H41290
6 3f 5-Cl4-t-BuC6H41291
7 3g 5-Cl3,5-(CH3)2C6H31292
8 3h 5-Cl3-Cl-4-FC6H31590
9 3i 5-Cl2-CH3CH2C6H41293
10 3j 5-Cln-C4H91589
11 3k 5-F4-CH3C6H41292
12 3l 5-F4-ClC6H41291
13 3m 5-F2,4-(CH3)2C6H31291
14 3n 5-F3-Cl-4-FC6H31590
15 3o 5-F4-t-BuC6H41292
16 3p 5-F2-CH3CH2C6H41292
17 3q 5-Br4-ClC6H41293
18 3r 5-Br3-Cl-4-FC6H31590
19 3s 5-Br4-BrC6H41290
20 3t 5-Br3,5-(CH3)2C6H31291
21 3u 5-Brn-C4H91592
Synthesis of dihydropyrrolo[2,3,4-kl]acridines 3. To expand the scope of the present method, N-substituted 3-aminocyclohex-2-enone, N-substituted 3-amino-5-phenylcyclohex-2-enones or N-substituted 3-amino-5-methylcyclohex-2-enones (4) were examined to replace the N-substituted 3-amino-5,5-dimethylcyclohex-2-enones (2), to our surprise, under the above optimized conditions, the desired 4,5-dihydropyrrolo[2,3,4-kl]acridine products 3 were not obtained. In the corresponding 1H-NMR spectra, the methylene group signals could not be detected, however a new aromatic proton could be detected easily. This result indicated that the corresponding oxidation products, the pyrrolo[2,3,4-kl]acridine derivatives 5 were produced (Table 3). The reason is that when there is no substituent or only one substituene (phenyl or methyl) on the C5 position of N-substituted 3-aminocyclohex-2-enone, the 4,5-dihydropyrrolo[2,3,4-kl]acridine derivatives would be oxidized by oxygen in the air to give pyrrolo[2,3,4-kl]acridine derivatives. The reaction pathways could therefore be controlled by varying the enaminones with different substitution patterns to give a series of novel 4,5-dihydropyrrolo[2,3,4-kl]acridin-1-ones 3 and pyrrolo[2,3,4-kl]acridin-1-ones 5 selectively.
Table 3

Synthesis of pyrrolo[2,3,4-kl]acridine derivatives 5.

EntryProductR1R2R3Time (min)Isolated Yield (%)
1 5a 5-F4-ClC6H4H1587
2 5b 5-F2,4-Cl2C6H3H1588
3 5c 5-FC6H5H1587
4 5d 5-Cl4-BrC6H4H1588
5 5e 5-F4-t-BuC6H4H1586
6 5f 5-F4-ClC6H4Ph1587
7 5g 5-F3-Cl-4-FC6H3Ph1584
8 5h HC6H5Ph1588
9 5i 5-F2,4-(CH3)2C6H3Ph1585
10 5j H4-BrC6H4Ph1587
11 5k 5-Cl4-t-BuC6H4Ph1585
12 5l 5-FC6H5Ph1584
13 5m 5-Br4-CH3C6H4Ph1585
14 5n 5-Br4-OCH3C6H4CH31585
Synthesis of pyrrolo[2,3,4-kl]acridine derivatives 5. The structures of the products 3 and 5were identified from their IR, 1H-NMR, and HRMS spectra. The structure of compound 3k was further confirmed by X-ray analysis (Figure 1).
Figure 1

Molecular structure of compound 3k.

Molecular structure of compound 3k.

3. Experimental

3.1. General

All reagents were purchased from commercial suppliers and used without further purification. Melting points are uncorrected. IR spectra were recorded on Varian F-1000 spectrometer in KBr with absorptions in cm−1. 1H-NMR (300 MHz or 400 MHz) spectra were recorded on a Varian Inova-300 MHz and Varian Inova-400 MHz (Palo Alto, CA, USA) in DMSO-d or CDCl3 solution. J values are in Hertz. Chemical shifts are expressed in parts per million downfield from internal standard TMS. High-resolution mass spectra (HRMS) for all the compounds were determined on Bruker MicrOTOF-QII mass spectrometer with ESI resource (Billerica, MA, USA). X-ray crystallographic analysis was performed with a Rigaku Mercury CCD/AFC diffractometer (Tokyo, Japan). Microwave irradiation was carried out with an Initiator EXP Microwave Synthesizer from Biotage (Uppsala, Sweden). The reaction temperature was measured by an infrared detector during microwave heating.

3.2. General Procedure for the Synthesis of Compounds 3 and 5

Isatin (1, 1.0 mmol) was introduced in a 10-mL Initiator reaction vial, and enaminone 2 or 4 (1.0 mmol) and 0.02 g of silica sulfuric acid as well as ethanol (3 mL) were then successively added. Subsequently, the reaction vial was closed and prestirred for 10 s. The mixture was irradiated (time, 12 or 15 min; temperature, 110 °C; absorption level, high; fixed hold time) until TLC (petroleum ether/ethyl acetate 3:1) revealed that convension of the starting material 1 was complete. The reaction mixture was then cooled to room temperature and concentrated. The solid was collected by Büchner filtration and purified by flash column chromatography (silica gel, mixture of petroleum ether/ethyl acetate, 3:1, v/v) to afford the desired products 3 or 5. 2-(4-tert-Butylphenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3a). M.p. 168–170 °C; IR (KBr, cm−1) 2930, 1690, 1448, 1332, 1075, 959, 891, 831, 700; 1H-NMR (400 MHz, DMSO-d): δ (ppm) 1.28 (s, 6H, 2 × CH3), 1.34 (s, 9H, (CH3)3), 3.33 (s, 2H, CH2), 5.80 (s, 1H, CH), 7.44 (d, J = 8.4 Hz, 2H, ArH), 7.59 (d, J = 8.4 Hz, 2H, ArH), 7.77 (t, J = 7.6 Hz, 1H, ArH), 7.84–7.88 (m, 1H, ArH), 8.16 (d, J = 8.8 Hz, 1H, ArH), 8.57 (d, J = 8.0 Hz, 1H, ArH). HRMS (ESI): m/z calcd. for C26H27N2O [M+H]+, 383.2123; found, 383.2103. 4,5-Dihydro-4,4-dimethyl-2-(3,5-dimethylphenyl)pyrrolo[2,3,4-kl]acridin-1(2H)-one (3b). M.p. 205–207 °C; IR (KBr, cm−1) 3064, 1717, 1634, 1499, 1386, 1327, 1257, 1186, 1092, 1018, 777; 1H-NMR (400 MHz, DMSO-d): δ (ppm) 1.20 (s, 6H, 2 × CH3), 2.30 (s, 6H, 2 × CH3), 3.07 (s, 2H, CH2), 5.64 (s, 1H, CH), 7.02–7.04 (m, 3H, ArH), 7.64 (t, J = 7.2 Hz, 1H, ArH), 7.72 (t, J = 7.6 Hz, 1H, ArH), 8.04 (d, J = 8.0 Hz, 1H, ArH), 8.46 (d, J = 7.6 Hz, 1H, ArH). HRMS (ESI): m/z calcd. for C24H23N2O [M+H]+, 355.1810; found, 355.1811. 2-(2-Ethylphenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3c). M.p. 196–198 °C; IR (KBr, cm−1) 2957, 1708, 1646, 1500, 1348, 1146, 1083, 1016, 896, 830, 738; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.39–1.40 (m, 9H, 3 × CH3), 2.39–2.43 (m, 2H, CH2), 3.32 (s, 2H, CH2), 5.82 (s, 1H, CH), 7.33–7.39 (m, 2H, ArH), 7.59–7.60 (m, 1H, ArH), 7.73–7.82 (m, 3H, ArH), 8.27–8.30 (m, 1H, ArH), 8.72–8.74 (m, 1H, ArH). HRMS (ESI): m/z calcd. for C24H23N2O [M+H]+, 355.1810; found, 355.1823. 2-(3-Chloro-4-fluorophenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3d). M.p. 168–169 °C; IR (KBr, cm−1) 2958, 1710, 1462, 1356, 1171, 1100, 880, 755; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.34 (s, 6H, 2 × CH3), 3.26 (s, 2H, CH2), 5.60 (s, 1H, CH), 7.31–7.38 (m, 2H, ArH), 7.56 (s, 1H, ArH), 7.69–7.78 (m, 2H, ArH), 8.20–8.21 (m, 1H, ArH), 8.69–8.70 (m, 1H, ArH). HRMS (ESI): m/z calcd. for C22H17ClFN2O [M+H]+, 379.1013; found, 379.1015. 9-Chloro-4,5-dihydro-2-(4-methoxyphenyl)-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3e). M.p. 162–164 °C; IR (KBr, cm−1) 2954, 1704, 1494, 1342, 1121, 1009, 819; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.32 (s, 6H, 2 × CH3), 3.18 (s, 3H, OCH3), 3.87 (s, 2H, CH2), 5.59 (s, 1H, CH), 7.04 (d, J = 6.6 Hz, 2H, ArH), 7.38 (d, J = 6.6 Hz, 2H, ArH), 7.65 (d, J = 7.2 Hz, 1H, ArH), 8.05 (d, J = 8.7 Hz, 1H, ArH), 8.66 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C23H20ClN2O2 [M+H]+, 391.1213; found, 391.1194. 2-(4-Tert-butylphenyl)-9-chloro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3f). M.p. 182–184 °C; IR (KBr, cm−1) 2947, 1575, 1485, 1392, 1319, 1253, 1077, 989, 833, 717; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.33 (s, 6H, 2 × CH3), 1.38 (s, 9H, (CH3)3), 3.19 (s, 2H, CH2), 5.68 (s, 1H, CH), 7.42 (s, 2H, ArH), 7.56–7.57 (m, 2H, ArH), 7.66–7.68 (m, 1H, ArH), 8.08–8.09 (m, 1H, ArH), 8.69 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C26H26ClN2O [M+H]+, 417.1734; found, 417.1768. 9-Chloro-4,5-dihydro-4,4-dimethyl-2-(3,5-dimethylphenyl)pyrrolo[2,3,4-kl]acridin-1(2H)-one (3g). M.p. 178–180 °C; IR (KBr, cm−1) 2928, 1705, 1636, 1521, 1474, 1396, 1254, 1176, 1109, 1035, 803; 1H-NMR (400 MHz, DMSO-d): δ (ppm) 1.11 (s, 6H, 2 × CH3), 2.21 (s, 6H, 2 × CH3), 2.97 (s, 2H, CH2), 5.61 (s, 1H, CH), 6.94 (s, 3H, ArH), 7.61–7.65 (m, 1H, ArH), 7.91 (d, J = 8.8 Hz, 1H, ArH), 8.23 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C24H22ClN2O [M+H]+, 389.1421; found, 389.1405. 9-Chloro-2-(3-chloro-4-fluorophenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3h). M.p. 164–166 °C; IR (KBr, cm−1) 2944, 1634, 1484, 1369, 1288, 1182, 1093, 951, 818, 693; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.34 (s, 6H, 2 × CH3), 3.20 (s, 2H, CH2), 5.63 (s, 1H, CH), 7.32–7.37 (m, 2H, ArH), 7.57 (s, 1H, ArH), 7.69 (d, J = 7.8 Hz, 1H, ArH), 8.09 (d, J = 7.8 Hz, 1H, ArH), 8.66 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C22H16 Cl2FN2O [M+H]+, 413.0624; found: 413.0608. 9-Chloro-2-(2-ethylphenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3i). M.p. 198–200 °C; IR (KBr, cm−1) 2948, 1703, 1638, 1516, 1457, 1351, 1209, 1087, 910, 879, 804; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.14–1.16 (m, 3H, CH3), 1.31 (s, 6H, 2 × CH3), 2.56 (s, 2H, CH2), 3.20 (s, 2H, CH2), 5.29 (s, 1H, CH), 7.27 (s, 1H, ArH), 7.36 (s, 1H, ArH), 7.45 (s, 2H, ArH), 7.67 (d, J = 8.1 Hz, 1H, ArH), 8.09 (d, J = 6.9 Hz, 1H, ArH), 8.69 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C24H22ClN2O [M+H]+, 389.1421; found, 389.1416. 2-Butyl-9-chloro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3j). M.p. 148–149 °C; IR (KBr, cm−1) 2950, 1706, 1500, 1346, 1240, 1091, 956, 890, 824, 697; 1H-NMR (300 MHz, CDCl3): δ (ppm) 0.92–0.94 (m, 3H, CH3), 1.29–1.36 (m, 8H, CH2 + 2 × CH3), 1.66–1.67 (m, 2H, CH2), 3.09–3.10 (m, 2H, CH2), 3.73–3.74 (m, 2H, CH2), 5.51 (s, 1H, CH), 7.57–7.58 (m, 1H, ArH), 7.96–7.98 (m, 1H, ArH), 8.56 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C20H22ClN2O [M+H]+, 341.1421; found, 341.1412. 2-(4-tert-Butylphenyl)-9-fluoro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3k). M.p. 168–170 °C; IR (KBr, cm−1) 3079, 1711, 1635, 1504, 1403, 1256, 1119, 1063, 775, 707; 1H-NMR (400 MHz, DMSO-d): δ (ppm) 1.24 (s, 6H, 2 × CH3), 2.38 (s, 3H, CH3), 3.08 (s, 2H, CH2), 5.70 (s, 1H, CH), 7.31–7.36 (m, 4H, ArH), 7.60 (s, 1H, ArH), 8.00–8.09 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C23H20FN2O [M+H]+, 359.1560; found, 359.1544. 2-(4-Chlorophenyl)-9-fluoro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3l). M.p. 192–195 °C; IR (KBr, cm−1) 2957, 1703, 1508, 1360, 1223, 1110, 825, 699; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.32 (s, 6H, 2 × CH3), 3.19 (s, 2H, CH2), 5.63 (s, 1H, CH), 7.44–7.52 (s, 5H, ArH), 8.12–8.16 (m, 1H, ArH), 8.28–8.31 (m, 1H, ArH). HRMS (ESI): m/z calcd. for C22H17ClFN2O [M+H]+, 379.1013; found, 379.1005. 9-Fluoro-4,5-dihydro-4,4-dimethyl-2-(2,4-dimethylphenyl)pyrrolo[2,3,4-kl]acridin-1(2H)-one (3m). M.p. 148–150 °C; IR (KBr, cm−1) 2940, 1697, 1602, 1454, 1354, 1251, 1096, 970, 896, 834, 707; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.28 (s, 6H, 2 × CH3), 2.06 (s, 3H, CH3), 2.35 (s, 3H, CH3), 3.17 (s, 2H, CH2), 5.28 (s, 1H, CH), 7.13 (s, 1H, ArH), 7.24 (s, 2H, ArH), 7.46–7.48 (m, 1H, ArH), 8.12–8.14 (m, 1H, ArH), 8.28–8.31 (m, 1H, ArH). HRMS (ESI): m/z calcd. for C24H22FN2O [M+H]+, 373.1716; found, 373.1699. 2-(3-Chloro-4-fluorophenyl)-9-fluoro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3n). M.p. 172–173 °C; IR (KBr, cm−1) 2958, 1613, 1473, 1363, 1273, 1171, 1070, 998, 910, 827, 701; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.33 (s, 6H, 2 × CH3), 3.22 (s, 2H, CH2), 5.63 (s, 1H, CH), 7.30–7.36 (m, 2H, ArH), 7.48–7.57 (m, 2H, ArH), 8.14–8.18 (m, 1H, ArH), 8.25–8.27 (m, 1H, ArH). HRMS (ESI): m/z calcd. for C22H16ClF2N2O [M+H]+, 397.0919; found, 397.0927. 2-(4-tert-Butylphenyl)-9-fluoro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3o). M.p. 204–206 °C; IR (KBr, cm−1) 2950, 1707, 1639, 1493, 1348, 1201, 1086, 1017, 955, 833; 1H-NMR (400 MHz, DMSO-d): δ (ppm) 1.19 (s, 6H, 2 × CH3), 1.27 (s, 9H, (CH3)3), 3.04 (s, 2H, CH2), 5.70 (s, 1H, CH), 7.36–7.37 (m, 2H, ArH), 7.51–7.59 (m, 3H, ArH), 7.97 (s, 1H, ArH), 8.07 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C26H26FN2O [M+H]+, 401.2029; found, 401.2034. 2-(2-Ethylphenyl)-9-fluoro-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3p). M.p. 166–168 °C; IR (KBr, cm−1) 2949, 1699, 1514, 1353, 1196, 1098, 1017, 943, 843, 785; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.12–1.17 (m, 3H, CH3), 1.30 (s, 6H, 2 × CH3), 2.53–2.56 (m, 2H, CH2), 3.20 (s, 2H, CH2), 5.28 (s, 1H, CH), 7.27 (s, 1H, ArH), 7.35 (s, 1H, ArH), 7.44–7.46 (m, 2H, ArH), 7.50–7.53 (m, 1H, ArH), 8.15–8.18 (m, 1H, ArH), 8.33 (d, J = 6.3 Hz, 1H, ArH). HRMS (ESI): m/z calcd. for C24H22FN2O [M+H]+, 373.1716; found, 373.1712. 9-Bromo-2-(4-chlorophenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3q). M.p. 192–194 °C; IR (KBr, cm−1) 2949, 1705, 1499, 1351, 1102, 961, 826, 740; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.32 (s, 6H, 2 × CH3), 3.17 (s, 2H, CH2), 5.64 (s, 1H, CH), 7.44–7.49 (m, 4H, ArH), 7.80 (s, 1H, ArH), 7.97 (s, 1H, ArH), 8.81 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C22H17BrClN2O [M+H]+, 439.0213; found, 439.0197. 9-Bromo-2-(3-chloro-4-fluorophenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3r). M.p. 168–170 °C; IR (KBr, cm−1) 2950, 1704, 1588, 1495, 1439, 1347, 1084, 822, 702; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.33 (s, 6H, 2 × CH3), 3.18 (s, 2H, CH2), 5.63 (s, 1H, CH), 7.30–7.36 (m, 2H, ArH), 7.56 (s, 1H, ArH), 7.79 (d, J = 6.6 Hz, 1H, ArH), 7.98 (d, J = 8.4 Hz, 1H, ArH), 8.77 (s, 1H, CH). HRMS (ESI): m/z calcd. for C22H16BrClFN2O [M+H]+, 457.0119; found, 457.0103. 9-Bromo-2-(4-bromophenyl)-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3s). M.p. 182–184 °C; IR (KBr, cm−1)2955, 1709, 1590, 1459, 1343, 1159, 1013, 889, 832, 766, 705; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.32 (s, 6H, 2 × CH3), 3.18 (s, 2H, CH2), 5.64 (s, 1H, CH), 7.37–7.39 (m, 2H, ArH), 7.65 (s, 2H, ArH), 7.79–7.82 (m, 1H, ArH), 7.99 (d, J = 6.9 Hz, 1H, ArH), 8.82 (s, 1H, CH). HRMS (ESI): m/z calcd. for C22H17 Br2N2O [M+H]+, 482.9708; found, 482.9693. 9-Bromo-4,5-dihydro-4,4-dimethyl-2-(3,5-dimethylphenyl)pyrrolo[2,3,4-kl]acridin-1(2H)-one (3t). M.p. 164–166 °C; IR (KBr, cm−1) 2958, 1915, 1612, 1550, 1445, 1318, 1229, 1101, 984, 823, 715; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.31 (s, 6H, 2 × CH3), 2.39 (s, 6H, 2 × CH3), 3.16 (s, 2H, CH2), 5.63 (s, 1H, CH), 7.03–7.07 (m, 3H, ArH), 7.22 (d, J = 6.0 Hz, 1H, ArH), 7.96–7.98 (m, 1H, ArH), 8.83 (s, 1H, CH). HRMS (ESI): m/z calcd. for C24H22BrN2O [M+H]+, 433.0916; found, 433.0906. 9-Bromo-2-butyl-4,5-dihydro-4,4-dimethylpyrrolo[2,3,4-kl]acridin-1(2H)-one (3u). M.p. 156–158 °C; IR (KBr, cm−1) 2938, 1699, 1510, 1450, 1356, 1245, 1126, 1028, 831, 789; 1H-NMR (300 MHz, CDCl3): δ (ppm) 0.95 (s, 3H, CH3), 1.32–138 (m, 8H, CH2 + 2 × CH3), 1.69–1.70 (m, 2H, CH2), 3.11–3.12 (m, 2H, CH2), 3.77 (s, 2H, CH2), 5.54 (s, 1H, CH), 7.74 (d, J = 7.2 Hz, 1H, ArH), 7.94 (d, J = 8.7 Hz, 1H, ArH), 8.78 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C20H22BrN2O [M+H]+, 385.0916; found, 385.0917. 2-(4-Chlorophenyl)-9-fluoropyrrolo[2,3,4-kl]acridin-1(2H)-one (5a). M.p. 237–238 °C; IR (KBr, cm−1) 3022, 1716, 1638, 1185, 1074, 874; 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.02–7.04 (m, 1H, ArH), 7.56–7.59 (m, 4H, ArH), 7.69–7.73 (m, 2H, ArH), 7.90 (d, J = 9.2 Hz 1H, ArH), 8.44–8.50 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C20H10ClFN2NaO, 371.0363, [M+Na]+; found, 371.0345. 2-(2,4-Dichlorophenyl)-9-fluoropyrrolo[2,3,4-kl]acridin-1(2H)-one (5b). M.p. 248–250 °C; IR (KBr, cm−1) 3050, 1723, 1639, 1182, 1089, 785; 1H-NMR (400 MHz, CDCl3): δ (ppm) 6.66 (d, J = 6.8 Hz 1H, ArH), 7.43–7.45 (m, 1H, ArH), 7.58 (d, J = 8.0 Hz, 2H, ArH), 7.69–7.73 (m, 2H, ArH), 7.92 (d, J = 8.8 Hz 1H, ArH), 8.49–8.53 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C20H9Cl2FN2NaO, 404.9974, [M+Na]+; found, 404.9989. 9-Fluoro-2-phenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5c). M.p. 228–230 °C; IR (KBr, cm−1) 2978, 1716, 1673, 1262, 1185, 1074, 874; 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.03 (d, J = 6.8 Hz 1H, ArH), 7.46–7.47 (m, 1H, ArH), 7.60–7.76 (m, 6H, ArH), 7.87 (d, J = 8.8 Hz 1H, ArH), 8.43–8.50 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C20H11FN2NaO, 337.0753, [M+Na]+; found, 337.0769. 2-(4-Bromophenyl)-9-chloropyrrolo[2,3,4-kl]acridin-1(2H)-one (5d). M.p. 218–220 °C; IR (KBr, cm−1) 2978, 1706, 1632, 1503, 1130, 1118 1096, 854; 1H-NMR (400 MHz, CDCl3): δ (ppm) 6.70–6.71 (m, 1H, ArH), 7.48–7.59 (m, 3H, ArH), 7.64–7.71 (m, 3H, ArH), 7.87–7.89 (m, 1H, ArH), 8.43–8.49 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C20H10BrClN2NaO, 430.5963, [M+Na]+; found, 430.5978. 2-(4-tert-Butylphenyl)-9-fluoropyrrolo[2,3,4-kl]acridin-1(2H)-one (5e). M.p. 162–164 °C; IR (KBr, cm−1) 2951, 1710, 1628, 1512, 1353, 1205, 1096, 830, 718; 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.42 (s, 9H, C(CH3)3), 7.04–7.06 (m, 1H, ArH), 7.57–7.71 (m, 6H, ArH), 7.85–7.89 (m, 1H, ArH), 8.44–8.51 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C24H20FN2O, 370.1481, [M+H]+; found, 371.1537. 2-(4-Chlorophenyl)-9-fluoro-4-phenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5f). M.p. 238–240 °C; IR (KBr, cm−1) 2930, 2352, 1710, 1640, 1503, 1384, 1092, 805; 1H-NMR (300 MHz, CDCl3): δ (ppm) 7.46–7.69 (m, 11H, ArH), 8.04–8.05 (m, 1H, ArH), 8.41–8.42 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C26H15ClFN2O, 425.0857, [M+H]+; found, 425.0846. 2-(3-Chloro-4-fluorophenyl)-9-fluoro-4-phenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5g). M.p. 230–232 °C; IR (KBr, cm−1) 3069, 2926, 2354, 1716, 1639, 1499, 1087, 812; 1H-NMR (300 MHz, CDCl3): δ (ppm) 7.29–7.54 (m, 6H, ArH), 7.70–7.76 (m, 4H, ArH), 8.01–8.02 (m, 1H, ArH), 8.42–8.45 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C26H14 ClF2N2O, 443.0763 [M+H]+; found, 443.0770. 2,4-Diphenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5h). M.p. 220–221 °C; IR (KBr, cm−1) 2921, 1718, 1637, 1496, 1103, 1008, 761; 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.27 (s, 1H, ArH), 7.45–7.53 (m, 4H, ArH), 7.60–7.73 (m, 6H, ArH), 7.80 (t, J = 8.0 Hz, 1H, ArH), 7.93 (t, J = 8.4 Hz, 1H, ArH), 8.06 (s, 1H, ArH), 8.42 (d, J = 8.8 Hz, 1H, ArH), 8.89 (d, J = 8.0 Hz, 1H, ArH). HRMS (ESI): m/z calcd. for C26H16N2NaO, 395.1160 [M+Na]+; found, 395.1182. 9-Fluoro-2-(2,4-dimethylphenyl)-4-phenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5i). M.p. 188–190 °C; IR (KBr, cm−1) 2990, 1705, 1633, 1131, 1066, 854; 1H-NMR (400 MHz, CDCl3): δ (ppm) 2.08 (s, 3H, CH3), 2.26 (s, 3H, CH3), 6.72–6.73 (m, 1H, ArH), 7.03–7.16 (m, 3H, ArH), 7.22–7.29 (m, 3H, ArH), 7.47–7.49 (m, 3H, ArH), 7.82–7.84 (m, 1H, ArH), 8.22–8.27 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C28H20FN2O, 419.1560, [M+H]+; found, 419.1559. 2-(4-Bromophenyl)-4-phenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5j). M.p. 234–235 °C; IR (KBr, cm−1) ν2987, 1703, 1636, 1501, 1253, 1181, 1085, 832. 1H-NMR (CDCl3-d, 400 MHz) δ : 7.22 (s, 1H, ArH), 7.40–7.56 (m, 5H, ArH), 7.69–7.79 (m, 5H, ArH), 7.91 (t, J = 7.6 Hz, 1H, ArH), 8.05 (s, 1H, ArH), 8.40 (d, J = 8.8 Hz, 1H, ArH), 8.83 (d, J = 8.4 Hz, 1H, ArH). HRMS (ESI): m/z calcd. for C26H16BrN2O, 451.0446, [M+H]+; found, 451.0409. 2-(4-tert-Butylphenyl)-9-chloro-4-phenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5k). M.p. 222–223 °C; IR (KBr, cm−1) 2922, 1719, 1634, 1383, 1171, 1077, 822; 1H-NMR (400 MHz, CDCl3): δ (ppm) 1.42 (s, 9H, (CH3)3), 7.19–7.22 (m, 1H, ArH), 7.42–7.68 (m, 9H, ArH), 7.75–7.80 (m, 1H, ArH), 7.92–7.96 (m, 1H, ArH), 8.27–8.31 (m, 1H, ArH), 8.73–8.78 (m, 1H, ArH) HRMS (ESI): m/z calcd. for C30H24ClN2O, 463.1577, [M+H]+; found, 463.1570. 9-Fluoro-2,4-diphenylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5l). M.p. 218–219 °C; IR (KBr, cm−1) 2957, 1705, 1633, 1322, 1173, 1096, 854; 1H-NMR (400 MHz, CDCl3): δ (ppm) 7.43–7.51 (m, 4H, ArH), 7.59–7.70 (m, 8H, ArH), 8.01–8.02 (m, 1H, ArH), 8.41–8.43 (m, 2H, ArH). HRMS (ESI): m/z calcd. for C26H16FN2O, 391.1247, [M+H]+; found, 391.1229. 9-Bromo-4-phenyl-2-p-tolylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5m). M.p. 220–222 °C; IR (KBr, cm−1) 2921, 1706, 1635, 1384, 1129, 1092, 820; 1H-NMR (400 MHz, CDCl3): δ (ppm) 2.45 (s, 3H, CH3), 7.17 (s, 1H, ArH), 7.38–7.50 (m, 7H, ArH), 7.65 (d, J = 7.6 Hz, 2H, ArH), 7.89–7.95 (m, 2H, ArH), 8.21 (d, J = 9.2 Hz, 1H, ArH), 8.98 (s, 1H, ArH). HRMS (ESI): m/z calcd. for C27H17BrN2NaO, 487.0422, [M+H]+; found, 487.0403. 9-Bromo-2-(4-methoxyphenyl)-4-methylpyrrolo[2,3,4-kl]acridin-1(2H)-one (5n). M.p. 216–218 °C; IR (KBr, cm−1) 2916, 1718, 1637, 1516, 1384, 1124, 1080, 849; 1H-NMR (400 MHz, CDCl3): δ (ppm) 2.50 (s, 3H, CH3), 2.60 (s, 3H, OCH3), 6.82 (s, 1H, ArH), 7.41–7.60 (m, 5H, ArH), 7.93–7.96 (m, 1H, ArH), 8.24–8.26 (m, 1H, ArH), 9.03–9.04 (m, 1H, ArH). HRMS (ESI): m/z calcd. for C22H15BrN2NaO2, 441.0215, [M+Na]+; found, 441.0218.

4. Conclusions

In conclusion, we have developed a procedure for the simple synthesis of a variety of potential biologically active pyrrolo[2,3,4-kl]acridines based on a novel domino reaction. Using this method, a library of molecularly diverse pyrrolo[2,3,4-kl]acridine derivatives was rapidly assembled (12–15 min) with excellent yields (84%–93%) by using readily available and inexpensive substrates under microwave irradiation.
  12 in total

1.  Amphiphilic helical peptides containing two acridine moieties display picomolar affinity toward HIV-1 RRE and TAR.

Authors:  Yeongran Lee; Soonsil Hyun; Hyun Jin Kim; Jaehoon Yu
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.

Authors:  Naval Kapuriya; Kalpana Kapuriya; Xiuguo Zhang; Ting-Chao Chou; Rajesh Kakadiya; Yu-Tse Wu; Tung-Hu Tsai; Yu-Ting Chen; Te-Chang Lee; Anamik Shah; Yogesh Naliapara; Tsann-Long Su
Journal:  Bioorg Med Chem       Date:  2008-04-15       Impact factor: 3.641

3.  An efficient synthesis of pyrrolo[2,3,4-kl]acridin-1-one derivatives catalyzed by L-proline.

Authors:  Huiyuan Wang; Lili Li; Wei Lin; Pan Xu; Zhibin Huang; Daqing Shi
Journal:  Org Lett       Date:  2012-08-24       Impact factor: 6.005

4.  Silica gel-catalyzed one-pot syntheses in water and fluorescence properties studies of 5-amino-2-aryl-3H-chromeno[4,3,2-de][1,6]naphthyridine-4-carbonitriles and 5-amino-2-aryl-3H-quinolino[4,3,2-de][1,6]naphthyridine-4-carbonitriles.

Authors:  Hui Wu; Wei Lin; Yu Wan; Hai-qiang Xin; Da-qing Shi; Yan-hui Shi; Rui Yuan; Rong-cheng Bo; Wei Yin
Journal:  J Comb Chem       Date:  2010 Jan-Feb

5.  A domino synthetic strategy leading to two-carbon-tethered fused acridine/indole pairs and fused acridine derivatives.

Authors:  Bo Jiang; Xue Wang; Meng-Yuan Li; Qiong Wu; Qin Ye; Hai-Wei Xu; Shu-Jiang Tu
Journal:  Org Biomol Chem       Date:  2012-09-26       Impact factor: 3.876

6.  Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

Authors:  Lisa M Oppegard; Andrei V Ougolkov; Doris N Luchini; Renee A Schoon; John R Goodell; Harneet Kaur; Daniel D Billadeau; David M Ferguson; Hiroshi Hiasa
Journal:  Eur J Pharmacol       Date:  2008-12-03       Impact factor: 4.432

7.  Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents.

Authors:  Caterina Fattorusso; Giuseppe Campiani; Gagan Kukreja; Marco Persico; Stefania Butini; Maria Pia Romano; Maria Altarelli; Sindu Ros; Margherita Brindisi; Luisa Savini; Ettore Novellino; Vito Nacci; Ernesto Fattorusso; Silvia Parapini; Nicoletta Basilico; Donatella Taramelli; Vanessa Yardley; Simon Croft; Marianna Borriello; Sandra Gemma
Journal:  J Med Chem       Date:  2008-02-16       Impact factor: 7.446

8.  Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.

Authors:  Nicolas Desbois; Maryline Gardette; Janine Papon; Pierre Labarre; Aurélie Maisonial; Philippe Auzeloux; Claire Lartigue; Bernadette Bouchon; Eric Debiton; Yves Blache; Olivier Chavignon; Jean-Claude Teulade; Jean Maublant; Jean-Claude Madelmont; Nicole Moins; Jean-Michel Chezal
Journal:  Bioorg Med Chem       Date:  2008-07-10       Impact factor: 3.641

9.  Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine.

Authors:  Carole Di Giorgio; Kamal Shimi; Gérard Boyer; Florence Delmas; Jean-Pierre Galy
Journal:  Eur J Med Chem       Date:  2007-03-01       Impact factor: 6.514

10.  Silica sulfuric acid promotes aza-Michael addition reactions under solvent-free condition as a heterogeneous and reusable catalyst.

Authors:  Yan Wang; Yan-Qin Yuan; Sheng-Rong Guo
Journal:  Molecules       Date:  2009-11-23       Impact factor: 4.411

View more
  2 in total

1.  One-Pot Syntesis of 3-Functionalized 4-Hydroxycoumarin under Catalyst-Free Conditions.

Authors:  Yang Gao; Guo-Ning Zhang; Juxian Wang; Xiaoguang Bai; Yiliang Li; Yucheng Wang
Journal:  Molecules       Date:  2018-01-22       Impact factor: 4.411

2.  An Efficient Synthesis of Acenaphtho[1,2-b]indole Derivatives via Domino Reaction.

Authors:  Guo-Ning Zhang; Xia Yuan; Weiping Niu; Mei Zhu; Juxian Wang; Yucheng Wang
Journal:  Molecules       Date:  2018-11-21       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.